Literature DB >> 25740874

Early-onset central diabetes insipidus is associated with de novo arginine vasopressin-neurophysin II or Wolfram syndrome 1 gene mutations.

Silverio Perrotta1, Natascia Di Iorgi1, Fulvio Della Ragione1, Saverio Scianguetta1, Adriana Borriello1, Anna Elsa Maria Allegri1, Marcella Ferraro1, Claudia Santoro1, Flavia Napoli1, Annalisa Calcagno1, Marta Giaccardi1, Marco Cappa1, Maria Carolina Salerno1, Domenico Cozzolino1, Mohamad Maghnie2.   

Abstract

OBJECTIVE: Idiopathic early-onset central diabetes insipidus (CDI) might be due to mutations of arginine vasopressin-neurophysin II (AVP-NPII (AVP)) or wolframin (WFS1) genes. DESIGN AND METHODS: Sequencing of AVP and WFS1 genes was performed in nine children with CDI, aged between 9 and 68 months, and negative family history for polyuria and polydipsia.
RESULTS: Two patients carried a mutation in the AVP gene: a heterozygous G-to-T transition at nucleotide position 322 of exon 2 (c.322G>T) resulting in a stop codon at position 108 (p.Glu108X), and a novel deletion from nucleotide 52 to 54 (c.52_54delTCC) producing a deletion of a serine at position 18 (p.Ser18del) of the AVP pre-prohormone signal peptide. A third patient carried two heterozygous mutations in the WFS1 gene localized on different alleles. The first change was A-to-G transition at nucleotide 997 in exon 8 (c.997A>G), resulting in a valine residue at position 333 in place of isoleucine (p.Ile333Val). The second novel mutation was a 3 bp insertion in exon 8, c.2392_2393insACG causing the addition of an aspartate residue at position 797 and the maintenance of the correct open reading frame (p. Asp797_Val798insAsp). While similar WFS1 protein levels were detected in fibroblasts from healthy subjects and from the patient and his parents, a major sensitivity to staurosporine-induced apoptosis was observed in the patient fibroblasts as well as in patients with Wolfram syndrome.
CONCLUSIONS: Early-onset CDI is associated with de novo mutations of the AVP gene and with hereditary WFS1 gene changes. These findings have valuable implications for management and genetic counseling.
© 2015 European Society of Endocrinology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25740874     DOI: 10.1530/EJE-14-0942

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  6 in total

1.  Juvenile diabetes and visual impairment: Wolfram syndrome.

Authors:  A K Annamalai; S Ellard; M Shanmugam; T P Jai Juganya; E De Franco
Journal:  QJM       Date:  2019-10-01

2.  Two novel mutations in seven Czech and Slovak kindreds with familial neurohypophyseal diabetes insipidus-benefit of genetic testing.

Authors:  Gabriela Hrčková; Viktor Jankó; Jitka Kytnarová; Michaela Čižmárová; Markéta Tesařová; Ľudmila Košťálová; Daniela Virgová; Tomáš Dallos; Václav Hána; Jan Lebl; Jiří Zeman; László Kovács
Journal:  Eur J Pediatr       Date:  2016-08-18       Impact factor: 3.183

Review 3.  Arginine vasopressin (AVP): a review of its historical perspectives, current research and multifunctional role in the hypothalamo-hypophysial system.

Authors:  Fabio Rotondo; Henriett Butz; Luis V Syro; George M Yousef; Antonio Di Ieva; Lina M Restrepo; Andres Quintanar-Stephano; Istvan Berczi; Kalman Kovacs
Journal:  Pituitary       Date:  2016-08       Impact factor: 4.107

Review 4.  Diabetes insipidus: The other diabetes.

Authors:  Sanjay Kalra; Abdul Hamid Zargar; Sunil M Jain; Bipin Sethi; Subhankar Chowdhury; Awadhesh Kumar Singh; Nihal Thomas; A G Unnikrishnan; Piya Ballani Thakkar; Harshad Malve
Journal:  Indian J Endocrinol Metab       Date:  2016 Jan-Feb

Review 5.  Central diabetes insipidus.

Authors:  Hiroshi Arima; Yoshinori Azuma; Yoshiaki Morishita; Daisuke Hagiwara
Journal:  Nagoya J Med Sci       Date:  2016-12       Impact factor: 1.131

6.  A Rare Case of Familial Neurogenic Diabetes Insipidus in a 22-Year-Old Man.

Authors:  Van T T Phan; Zachary W Bloomer; Vien T X Phan; Mohamed K M Shakir; Thanh D Hoang
Journal:  AACE Clin Case Rep       Date:  2020-11-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.